Trial Profile
Phase II study of Tarceva [erlotinib] plus Temodar [temozolomide] during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Temozolomide
- Indications Brain cancer; Glioblastoma; Sarcoma
- Focus Therapeutic Use
- 29 Oct 2005 New trial record.